Effect of extracorporeal membrane oxygenation combined with ulinastatin

Abstract

This study aims to investigate the clinical efficacy of combining extracorporeal membrane oxygenation (ECMO) with ulinastatin in the treatment of severe pneumonia (SP) with respiratory failure, using an immuno-magnetic bead-based ELISA method. A total of 40 patients with SP complicated by respiratory failure who were admitted to the respiratory department of our hospital from January 2019 to December 2022, were selected. They were divided into the control group (n = 20) and the ECMO group (n = 20). The control group received conventional therapy such as mechanical ventilation, anti-infection, anticoagulation, and maintaining acid-base balance. The ECMO group established an ECMO system and injected ulinastatin intravenously based on conventional therapy. After 7 days of treatment, arterial blood was collected for blood gas analysis and pulmonary function index. The level of inflammatory factors was determined using the immunomagnetic bead-ELISA method. Flow cytometry was used to assess T lymphocyte subsets and clinical efficacy between the two groups. The ECMO group exhibited significantly shorter length of hospital stay and mechanical ventilation duration compared to the control group. Moreover, pulmonary function indexes (FEV1, FVC, PEF) and blood gas indexes were superior in the ECMO group than those in the control group. Additionally, the ECMO group exhibited significantly reduced levels of PCT, IL6, and CRP, and elevated CD3+% and CD4+% values compared to the control group. In conclusion, the combined therapy demonstrates efficacy in the treatment of patients with SP and respiratory failure, and the immunomagnetic bead-based ELISA method enhances detection efficiency and reduces errors.